Detailed price information for Bionxt Solutions Inc. (BNXT-CN) from The Globe and Mail including charting and trades.

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the ...

H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway. H2 2025: Target submission of New Drug Application (NDA). Sublingual ED medication H1 2026: Finalize formulation and manufacture test ...

Discover a new low-dose, inexpensive, at-home treatment for depression that is revolutionizing the treatment of ...

Findings showed MELT-300 was statistically superior to both sublingual midazolam and placebo for providing successful procedural sedation. Topline results were announced from a phase 3 trial ...

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing.

Buprenorphine sublingual tablet is prescribed to treat opioid use disorder in two phases: an induction phase to manage initial withdrawal symptoms and a maintenance phase for long-term treatment. You ...

The US Food and Drug Administration (FDA) has approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence, which may increase ...

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran ®, was the 53rd most commonly ...

H1 2026: Finalize formulation and manufacture test product. H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study. "Our pipeline is focused on research in therapeutic areas where we can ...